What’s new

• Commercial-stage CDMO projects dropped to 35 from 40 in the previous quarter.
• Management targets 15-18% revenue and EBITDA CAGR over the next 3-4 years.
• A ₹400 crore capex plan is set for FY27, with intensity expected to drop from FY28.

Why it matters

The contraction in commercial-stage projects creates a tension with the aggressive 40-50% growth guidance. While management maintains a 20% EBITDA margin floor, the refusal to provide specific FY27 profit guidance suggests they expect the near-term margin compression to be persistent.

What we’re watching

• Whether the project pipeline recovers in the coming quarters.
• The impact of West Asia-linked raw material inflation on margins.
• Actual capital expenditure execution against the ₹400 crore target.

The full read

Aarti Pharmalabs is betting on a 40-50% surge in its CDMO business for FY27, even as its commercial-stage project pipeline thins. The company reported a decline in active commercial projects to 35, down from 40 in the previous quarter. Management maintains a long-term revenue and EBITDA CAGR target of 15-18% over the next 3-4 years. To reach these goals, the firm has earmarked ₹400 crore for capex in FY27, with the expectation that spending intensity will ease from FY28 as current greenfield projects wrap up. Despite the growth targets, management refused to provide specific FY27 profit guidance. They remain committed to an EBITDA margin floor above 20%, though they acknowledge near-term pressure from startup costs and raw material inflation linked to the crisis in West Asia. The next test is whether the project pipeline can stabilize while the company absorbs these costs.

Primary source: BSE · NSE

What’s new

• Standalone Q4 net profit fell to ₹62.03 crore from ₹88.85 crore a year ago.
• Full-year net profit dropped to ₹176.20 crore from ₹238.03 crore.
• The board recommended a final dividend of ₹2 per share.

Why it matters

The results show a clear trend of margin compression and rising finance costs weighing on the bottom line. This is a routine disclosure that confirms the pressure on profitability seen throughout the year.

What we’re watching

• Whether the company can stabilize margins in the coming quarters.
• Any management commentary on the trajectory of finance costs.
• The impact of the proposed dividend on cash reserves.

The full read

Aarti Pharmalabs closed FY2026 with a sharp decline in profitability as rising finance costs and margin compression took hold. Standalone net profit for the full year landed at ₹176.20 crore, a significant drop from the ₹238.03 crore recorded in the previous year.

Margins are shrinking.

The trend persisted into the final quarter, where standalone net profit fell to ₹62.03 crore from ₹88.85 crore a year earlier, and the board has recommended a final dividend of ₹2 per share to appease shareholders despite the cooling performance. These results are backward-looking and largely align with market expectations for the mid-cap pharmaceutical player, yet the core challenge remains the company's ability to manage its cost structure in an environment where finance expenses are aggressively eating into margins.

Primary source: BSE · NSE

What’s new

• Standalone net profit dropped to ₹62.03 cr in Q4 from ₹88.85 cr in the prior year.
• Full-year standalone profit fell to ₹176.20 cr from ₹238.03 cr.
• Margins compressed due to rising finance costs and foreign exchange losses.

Why it matters

Revenue growth is failing to translate into bottom-line performance. The combination of higher interest expenses and forex volatility is eating into profitability, making the margin compression the primary concern for investors.

What we’re watching

• Management's plan to mitigate rising finance costs.
• The impact of the previously omitted derivative contract on future cash flows.
• Whether operating margins stabilize in the coming quarters.

The full read

Aarti Pharmalabs reported a sharp decline in standalone profitability for both the fourth quarter and the full year of FY2026. Quarterly net profit fell to ₹62.03 crore, down from ₹88.85 crore in the same period last year. For the full year, profit dropped to ₹176.20 crore from ₹238.03 crore.

Margins are under pressure.

Although revenue from operations grew, the company struggled against rising finance costs and foreign exchange losses that eroded its bottom line. The board recommended a final dividend of ₹2 per share. Audited results include an emphasis of matter concerning a derivative contract that was previously omitted from the financial statements. This is a routine financial release, and the results align with market expectations.

Primary source: BSE · NSE

What’s new

• Standalone Q4 profit fell to ₹62.03 crore from ₹88.85 crore a year ago.
• Full-year profit dropped to ₹176.20 crore from ₹238.03 crore in FY2025.
• The board recommended a final dividend of ₹2 per share.

Why it matters

The earnings decline reflects persistent margin pressure and higher finance costs. The belated recognition of a derivative contract, while flagged by auditors, adds a layer of governance concern to an already difficult year.

What we’re watching

• Whether finance costs stabilize in the coming quarters.
• Any further disclosures regarding internal controls over derivative accounting.
• Management commentary on margin recovery paths.

The full read

Aarti Pharmalabs closed FY2026 with a sharp decline in profitability, as standalone net profit fell to ₹176.20 crore from ₹238.03 crore in FY2025. The Q4 performance was similarly weak, with profit dropping to ₹62.03 crore from ₹88.85 crore in the prior year. Management attributed the slide to margin compression and elevated finance costs. Beyond the operational results, the company disclosed a ₹29.73 crore fair value loss stemming from a derivative contract that was inadvertently omitted from the FY2025 accounts. While the auditor issued an unmodified opinion, the report includes an emphasis of matter regarding this accounting lapse. The board recommended a final dividend of ₹2 per share, maintaining its historical payout level. These results were largely anticipated by the market following earlier profit warnings, yet the combination of earnings decline and a governance-related accounting error leaves little room for optimism in the near term.

Primary source: BSE · NSE